Core 1: Administrative and Communication Core

核心 1：行政和沟通核心

• 批准号: 10226186
• 负责人: Nikhil C. Munshi
• 金额: $ 22.98万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226186
• 关键词: Address; Advisory Committees; Algorithms; Basic Science; Behavior; Cancer Center; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Dana-Farber Cancer Institute; Disease; France; Genomic Instability; Genomics; Goals; Grant; Innovative Therapy; Institutes; International; Laboratories; Lead; Link; Massachusetts; Molecular; Molecular Abnormality; Monitor; Multiple Myeloma; Outcome; Patients; Research; Research Personnel; Research Project Grants; Resources; Science; Site; Technology; Therapeutic; Time; Tissue Banks; Translational Research; Travel; cancer genomics; collaborative trial; data exchange; epigenomics; meetings; molecular targeted therapies; next generation; novel; pre-clinical; programs; sample collection; survival outcome; targeted treatment; translational medicine

Project summary (Core 1) This proposal brings together the translational medicine and research expertise of Dana-Farber Cancer Institute (DFCI), Dana Farber/Harvard Cancer Center, and Massachusetts Institute of Technology (MIT) with the clinical research strength of Intergroupe Francophone du Myeloma (IFM) in France and the genomics expertise of the Sanger Institute in the UK to develop a curative strategy for MM. In this international collaborative renewal application, we now propose to build on our highly successful genomic, preclinical, clinical, and administrative strengths to address the next generation of questions that will ultimately lead to therapeutic advances for cure. Most importantly, our current study has confirmed that achieving MRD negative status provides significantly superior survival outcome. In this proposal, we will now undertake an international collaborative trial to address the next most important issue of how MRD status will inform our therapeutic decision algorithm (Project 1). Importantly, the large number of uniformly treated patients will allow us to both identify genomic and epigenomic correlates of disease behavior (Project 2) and identify molecular circuits and validate novel combination targeted therapeutic approaches (Project 3) as well as to define the mechanisms and clinical implications of genomic instability in MM (Project 4). This unique international collaborative effort requires significant co-ordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between investigators at various dispersed sites. The key function of Core A is integration of the research efforts and communication between investigators. Scientific and administrative integration is essential to assure successful interaction between the four Projects, as well as between the laboratory and clinical components within and between projects in this multinational multi-institutional program. Therefore, this central core will provide the link between various projects and successfully co-ordinate the clinical study and the proposed correlative science. To aid in achieving these goals, Core A will: monitor the timely conduct of the clinical study and assure progress in tissue collection, processing and usage to co- ordinate interaction between the clinical and correlative science studies (Specific Aim 1); co-ordinate communication, and exchange of data between investigators at various international sites (Specific Aim 2); provide necessary resources, fiscal oversight and administrative support for projects and cores (Specific Aim 3); facilitate intra-programatic interactions, meetings, travel and Internal and External Advisory Committees (Specific Aim 4).

项目摘要（核心1） 该建议将Dana-Farber癌的转化医学和研究专业知识汇集在一起 Institute（DFCI），Dana Farber/哈佛癌症中心和马萨诸塞州理工学院（MIT） 法兰西群体间法语的临床研究强度和法国基因组学的临床研究强度 英国Sanger Institute的专业知识，以制定MM的治疗策略。在这个国际 合作续订应用程序，我们现在建议以我们非常成功的基因组，临床前， 临床和行政优势，以解决下一代问题，这些问题最终会导致 治疗的治疗进展。最重要的是，我们目前的研究证实，达到MRD负面 地位提供了明显优越的生存结果。在此提案中，我们现在将进行国际 协作试验，以解决MRD状态如何告知我们的治疗的下一个最重要的问题 决策算法（项目1）。重要的是，大量统一治疗的患者将使我们同时 鉴定疾病行为的基因组和表观基因组相关性（项目2），并确定分子回路和 验证新型组合靶向治疗方法（项目3）以及定义机制 MM基因组不稳定性的临床意义（项目4）。这项独特的国际合作努力 需要大量的努力协调，策略整合，监控和监督各种 各种分散站点的调查人员之间的功能和沟通。核心A的关键功能是 研究工作的整合和研究人员之间的沟通。科学和行政 集成对于确保四个项目之间的成功互动至关重要 该跨国多机构计划中和项目之间和之间的临床组件。 因此，此中心核心将提供各个项目之间的联系，并成功协调 临床研究和拟议的相关科学。为了帮助实现这些目标，核心A：监视 及时进行临床研究，并确保组织收集，加工和使用中的进展 临床和相关科学研究之间的纵坐标相互作用（特定目的1）；协调 在各个国际地点的调查人员之间进行沟通和数据交换（特定目的2）； 为项目和核心提供必要的资源，财政监督和行政支持（特定目的 3）;促进主要内部互动，会议，旅行以及内部和外部咨询委员会 （特定目标4）。